Welcome to our dedicated page for OCTAVE SPECIALTY GROUP SEC filings (Ticker: OSG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Octave Specialty Group, Inc. filings document the formal disclosure record for a specialty insurance company built around insurance distribution and underwriting businesses. Form 8-K reports cover quarterly results, P&C premium production, commission income, and segment commentary for Insurance Distribution and Everspan. Other current reports disclose material definitive agreements, including amendments to credit arrangements involving Octave subsidiaries and ArmadaCare-related borrowers.
Proxy filings cover annual meeting procedures, shareholder voting matters, board governance, and executive compensation. The record also includes capital-structure and governance disclosures for Octave common stock.
Octave Specialty Group, Inc. reported higher revenue but continued losses for the three and six months ended June 30, 2026. Total revenues from continuing operations rose to $82.995 million in the quarter (from $54.957 million) and $187.165 million year‑to‑date (from $117.713 million), driven mainly by Insurance Distribution commissions. Pretax loss from continuing operations narrowed to $11.671 million for the quarter and $15.015 million year‑to‑date, and net loss attributable to shareholders was $14.429 million for the quarter and $21.280 million for six months, or $(0.33) and $(0.47) per basic share from continuing operations, respectively.
At June 30, 2026, total assets were $2.281 billion and total stockholders’ equity was $817.845 million, with long‑term debt increasing to $155.459 million after an additional $40 million term loan used to acquire redeemable noncontrolling interests. Continuing operations used $20.310 million of operating cash year‑to‑date, while investing activities provided $48.015 million, largely from net sales and maturities of investments. During the quarter the buyer of Ambac Assurance‑related warrants cash‑settled conversion of 1,697,569 warrant shares for $4.855 million, leaving a warrant for 3,395,138 shares at an exercise price of $18.50 per share outstanding.
Octave Specialty Group, Inc. reported second quarter 2026 results with total revenue of $83.0 million, up 51% from $55.0 million a year earlier, driven mainly by its Insurance Distribution segment and the 2025 ArmadaCare acquisition. Net loss attributable to shareholders narrowed to $(14.4) million, or $(0.33) per diluted share, compared with $(72.7) million, or $(1.51) per share, in 2025.
Adjusted EBITDA to shareholders turned positive at $3.7 million versus a $(4.6) million loss, and adjusted net loss improved to $(1.8) million from $(10.6) million. Insurance Distribution revenue rose 77% to $58.4 million with organic revenue growth of 44.1%, while Adjusted EBITDA to shareholders climbed to $9.8 million from $2.5 million. Specialty P&C insurer Everspan generated net income of $1.1 million, improved its loss ratio to 61.4%, and reduced its combined ratio to 100.6%.
For the first half of 2026, total revenue reached about $187.2 million, and adjusted net income attributable to shareholders was $14.8 million. Stockholders’ equity attributable to common shareholders was $699 million, or $15.52 per share as of June 30, 2026. Octave also highlighted new data and AI initiatives, including a proprietary AI-driven underwriting platform, and scheduled an August 7, 2026 earnings call to discuss results and updated 2026 guidance.
Vanguard Capital Management and certain affiliates report beneficial ownership of common stock of Octave Specialty Group Inc. They beneficially own 2,269,979 shares of common stock, representing 5.04% of the class as of June 30, 2026.
Vanguard Capital Management has sole voting power over 297,360 shares and sole dispositive power over all 2,269,979 shares, with no shared voting or dispositive power. The position includes securities held by Vanguard funds and managed accounts over which Vanguard and the listed affiliates exercise dispositive and/or voting power, and excludes holdings of other disaggregated subsidiaries or affiliates. Dividends and sale proceeds are generally for the benefit of investment companies and other managed accounts, with no single other person holding more than 5% of the class through this position.
Octave Specialty Group Inc. Chief Executive Officer Claude LeBlanc reported equity compensation activity tied to his 2025 Long Term Incentive Plan. On July 9, 2026, 39,380 restricted stock units vested and were converted into common shares, with 21,777 shares withheld by the company at $6.08 per share to cover tax obligations. Following these transactions, LeBlanc holds 1,065,234 shares of common stock directly and 480,832 restricted stock units that remain outstanding and subject to future vesting through July 2028.
Octave Specialty Group Inc. executive Sharon R. Smith, Exec VP & Group COO, acquired common stock through the vesting and settlement of 11,779 Restricted Stock Units (RSUs) under her 2025 Long Term Incentive Plan. To cover tax obligations, 4,635 of the resulting shares were withheld by the company. Following these transactions, she holds 156,326 shares of common stock directly and 132,093 RSUs, which continue to vest in three equal annual installments on July 9, 2026, July 9, 2027, and July 9, 2028.
Octave Specialty Group Inc. executive vice president, CFO and treasurer David Trick reported routine equity compensation activity tied to his 2025 Long Term Incentive Plan. On July 9, 2026, 13,206 Restricted Stock Units vested and were settled into common shares, and 6,741 shares were withheld by the company at $6.08 per share to satisfy tax withholding obligations. Following these transactions, Trick directly holds 267,096 shares of common stock and 124,978 RSUs. The RSU award vests in three equal annual installments on July 9, 2026, July 9, 2027, and July 9, 2028.
Octave Specialty Group Inc. director Jeffrey Scott Stein received a grant of 6,500 restricted stock units (RSUs) linked to the company’s common stock. Each RSU represents a contingent right to receive one share of common stock, providing equity-based compensation rather than cash.
The RSUs were granted on July 1, 2026 and are scheduled to vest one year later on July 1, 2027. Once vested, they will convert into common shares when Stein leaves the Board of Directors or if a change of control of the company occurs. After this grant, his reported direct RSU holdings total 22,591 units.
Octave Specialty Group director Michael D. Price received a grant of 6,500 restricted stock units (RSUs) on July 1, 2026. Each RSU represents a contingent right to one share of common stock at no purchase price. These RSUs vest on July 1, 2027 and will convert into shares when he leaves the Board or if there is a change of control of the company. Following this grant, he directly holds 22,591 RSUs tied to Octave Specialty Group common stock.
Matus Kristi Ann reported acquisition or exercise transactions in this Form 4 filing.
Octave Specialty Group Inc director Kristi Ann Matus received a grant of 6,500 Restricted Stock Units (RSUs) on July 1, 2026. Each RSU represents a contingent right to receive one share of common stock. Following this award, she holds 22,591 shares-related units directly.
The RSUs granted on July 1, 2026 will vest on July 1, 2027. Once vested, they will settle into common shares when she leaves the Board of Directors or if there is a change of control of the company.
Octave Specialty Group Inc director Joan M. LammTennant received a grant of 6,500 Restricted Stock Units on July 1, 2026. Each RSU represents a contingent right to one share of common stock. After this award, she holds 22,591 RSUs directly.
The RSUs granted on July 1, 2026 are scheduled to vest on July 1, 2027. Once vested, they will convert into common shares when she leaves the Board of Directors or if there is a change of control at the company.